[New drugs in the treatment of noninfectious uveitis].
Cano-Parra
J
J
Díaz-Llopis
M
M
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000188:drug therapy; D002986:Clinical Trials as Topic; D000077561:Daclizumab; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D007267:Injections; D009798:Ocular Hypertension / Q000139:chemically induced; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014605:Uveitis / Q000188:drug therapy*; D014822:Vitreous Body
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D005446:Fluocinolone Acetonide; D000069285:Infliximab; D000077561:Daclizumab; D014222:Triamcinolone Acetonide